Vaccine prophylaxis during the covid-19 pandemic. Specific prevention of coronavirus infection technology platforms, including RNA and DNA
vaccines,
subunit recombinant, live-attenuated and viral vectors
Safety and immunogenicity of the gamtbvac, the recombinant subunit tuberculosis vaccine candidate: A phase II, multi-center, double-blind, randomized, placebo-controlled studyTkachuk A.P.,
Bykonia E.N.,
Popova L.I.,
Kleymenov D.A.,
Semashko M.A.,
Chulanov V.P.,
Fitilev S.B.,
Maksimov S.L.,
Smolyarchuk E.A.,
Manuylov V.A.,
Vasina D.V.,
Gushchin V.A.,
Gintsburg A.L. GamTBvac is a candidate tuberculosis
vaccine with two fusion proteins, containing Ag85a, ESAT6, CFP
Nanoparticle vaccines against infectious diseases of existing
vaccines against specific diseases. To date, some
vaccines are developed from protein
subunits Vaccines against Avian influenzae poultry.g.
subunit vaccines, VLP
vaccines, DNA
vaccines) were considered. The efficiency of influenza reverse genetic
Strategies for designing novel tuberculosis vaccines in the pipeline are considered. Special attention is paid to DNA- and protein
subunit vaccines. The most efficient
Various Adjuvants Effect on Immunogenicity of Puumala Virus VaccineVarious adjuvant effects on the immunogenicity of the candidate inactivated Puumala virus
vaccine Immune response to influenza vaccination in HIV patients vaccinated against influenza. A single dose of trivalent polymer-
subunit vaccine containing adjuvant